Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

View 0 Studies Requested

Browse Lab Results > 2010-0211

Trial Summary

About CDAS Project, PI, Publications: Inflammation markers and risk of endometrial and ovarian cancer

Datasets


Site: Endometrial

Inclusion Criteria:

  • Females in Intervention Arm
  • No Rare Cancers
  • No Prior History of Any Cancer
  • No Confirmed or Reported Cancers in Controls
  • No Hysterectomy
  • No Endometrial Cancers that are 2nd, reported, or unconfirmable
  • Has Any Serum Available
  • Has Pre-dx Serum Available
  • Frequency Matched at a 1-1 Ratio

Matching Factors:

  • Fiscal Year of Randomization
  • Age at Randomization (5 year intervals)
  • Race (White/Non-White)
  • Study Year of Blood Draw
  • Study Year of Exit

Match Ratio: 1 to 1

Match Technique: Frequency matching only non-cases as controls.


Analytes:

  • Adiponectin
  • Adipsin
  • B-Cell Attracting Chemokine 1
  • Basic Fibroblast Growth Factor
  • C-Reactive Protein
  • Chemokine (C-C Motif) Ligand 13
  • Chemokine (C-C Motif) Ligand 19
  • Chemokine (C-C Motif) Ligand 2
  • Chemokine (C-C Motif) Ligand 20
  • Chemokine (C-C Motif) Ligand 21
  • Chemokine (C-C Motif) Ligand 22
  • Chemokine (C-C Motif) Ligand 27
  • Chemokine (C-C Motif) Ligand 8
  • Chemokine (C-X-C Motif) Ligand 1
  • Chemokine (C-X-C Motif) Ligand 10
  • Chemokine (C-X-C Motif) Ligand 11
  • Chemokine (C-X-C Motif) Ligand 12
  • Chemokine (C-X-C Motif) Ligand 5
  • Chemokine (C-X-C Motif) Ligand 6
  • Chemokine (C-X-C Motif) Ligand 9
  • Eotaxin
  • Eotaxin-2
  • Epidermal Growth Factor
  • Estradiol
  • Granulocyte-Colony Stimulating Factor
  • Interleukin 1
  • Interleukin 1 Receptor Antagonist
  • Interleukin 16
  • Interleukin 29
  • Interleukin 33
  • Interleukin 7
  • Interleukin 8
  • Lipocalin-2
  • Macrophage Inflammatory Protein 1 delta
  • Macrophage inflammatory protein 1 beta
  • Plasminogen activator inhibitor-1
  • Resistin
  • Serum Amyloid A
  • Serum Amyloid P
  • Soluble Epidermal Growth Factor Receptor
  • Soluble Interleukin 4 Receptor
  • Soluble Interleukin 6 Receptor
  • Soluble Interleukin 6 beta
  • Soluble Tumor Necrosis Factor Receptor I
  • Soluble Tumor Necrosis Factor Receptor II
  • Stem Cell Factor
  • Thrombopoietin
  • Thymic Stromal Lymphopoietin
  • Thymus and Activation Regulated Chemokine
  • Transforming Growth Factor Alpha
  • Transforming Growth Factor Beta 1
  • Tumor Necrosis Factor Alpha 1
  • Tumor Necrosis Factor Beta
  • Tumor Necrosis Factor Receptor Superfamily, Member 10
  • Vascular Endothelial Growth Factor
  • Vascular endothelial growth factor receptor 2
  • Vascular endothelial growth factor receptor 3

Number of Cases: 284

Number of Controls: 284



Site: Ovary

Inclusion Criteria:

  • Females in Intervention Arm
  • No Rare Cancers in Controls
  • No Controls with Oophorectomies
  • 2+ Years Pre-Diagnostic Specimen Available

Matching Factors:

  • Age at Randomization (5 year intervals)
  • Race
  • Study Year of Blood Draw
  • Year of Blood Draw
  • Season of Blood Draw
  • Time of Blood Draw (am/pm)

Match Ratio: 1 to 1

Match Technique: Case cohort with controls matched to cases.

Additional Matching Comments: One cell had no matched controls; the case was kept.


Analytes:

  • Amylin
  • Basic Fibroblast Growth Factor
  • C-Peptide
  • C-Reactive Protein
  • Chemokine (C-C Motif) Ligand 2
  • Chemokine (C-C Motif) Ligand 22
  • Chemokine (C-X-C Motif) Ligand 1
  • Chemokine (C-X-C Motif) Ligand 10
  • Chemokine (C-X3-C Motif) Ligand 1
  • Chemokine Ligand 7
  • Eotaxin
  • Epidermal Growth Factor
  • Fms-related tyrosine kinase 3 ligand
  • Gastric inhibitory polypeptide
  • Glucagon
  • Glucagon-like peptide-1
  • Granulocyte-Colony Stimulating Factor
  • Granulocyte-Macrophage Colony Stimulating Factor
  • Insulin
  • Interferon alpha-2
  • Interferon-gamma
  • Interleukin 1
  • Interleukin 1 Receptor Antagonist
  • Interleukin 1 alpha
  • Interleukin 1 beta
  • Interleukin 10
  • Interleukin 12 p40
  • Interleukin 12 p70
  • Interleukin 15
  • Interleukin 17
  • Interleukin 2
  • Interleukin 3
  • Interleukin 4
  • Interleukin 5
  • Interleukin 6
  • Interleukin 7
  • Interleukin 8
  • Leptin
  • Macrophage Inflammatory Protein 1 alpha
  • Macrophage inflammatory protein 1 beta
  • Pancreatic Polipeptide
  • Pancreatic Polipeptide YY
  • Soluble Epidermal Growth Factor Receptor
  • Soluble Interleukin 1 Receptor Type 1
  • Soluble Interleukin 2 Receptor Alpha
  • Soluble Interleukin 4 Receptor
  • Soluble Interleukin 6 Receptor
  • Soluble Interleukin 6 beta
  • Soluble Receptor for Advanced Glycation Endproducts
  • Soluble Tumor Necrosis Factor Receptor I
  • Soluble Tumor Necrosis Factor Receptor II
  • Transforming Growth Factor Alpha
  • Tumor Necrosis Factor Alpha 1
  • Tumor Necrosis Factor Beta
  • Tumor Necrosis Factor Receptor Superfamily, Member 5
  • Tumor Necrosis Factor Receptor Superfamily, Member 8
  • Vascular Endothelial Growth Factor
  • Vascular endothelial growth factor receptor 1
  • Vascular endothelial growth factor receptor 2
  • Vascular endothelial growth factor receptor 3

Number of Cases: 150

Number of Controls: 169